🧪 Senolytics research: dasatinib + quercetin and fisetin — early human data
How science is learning to selectively eliminate senescent cells
Senolytics are agents that selectively trigger the death of senescent ("zombie") cells without harming normal ones. Senescent cells have stopped dividing but do not die: they release pro-inflammatory signals and accelerate tissue aging. The idea of "senotherapy" is to clear these cells from the body. Let's review the most studied candidates: the dasatinib + quercetin combination and fisetin.
What are senolytics
Senescent cells stop dividing but remain metabolically active. They release a set of pro-inflammatory factors — the so-called SASP (senescence-associated secretory phenotype), which contributes to chronic inflammation. For more on the phenomenon — see "Senescent cells and zombie cells".
Senolytics are drugs and natural substances that selectively kill such cells, triggering apoptosis in them. Unlike senostatics (which only suppress SASP), senolytics actually remove the cells from the body.
Discovery of the phenomenon
Pioneering work
James Kirkland's team (Mayo Clinic) showed in animals that removing senescent cells extends healthy life and improves tissue condition.
First senolytics
That year, dasatinib (an anticancer drug) and the natural flavonoid quercetin were described as the first effective senolytic combination.
Expanding the arsenal
Interest grew in fisetin and other natural compounds with senolytic activity.
The main discoveries were made in mice; the transition to human clinical trials began in the late 2010s.
Dasatinib + quercetin (D+Q)
Dasatinib is an approved anticancer drug (a tyrosine kinase inhibitor). Quercetin is a natural flavonoid common in plant foods. Together they show a synergistic senolytic effect.
In animals, the D+Q combination improved vessel, bone and heart function and reduced age-related impairments. In humans, effects are still being studied in small pilot trials.
Fisetin
Fisetin is a flavonoid found in strawberries, apples, persimmons and onions. It is considered one of the most potent natural senolytics and may be gentler on side effects than dasatinib.
Mouse studies showed that fisetin reduces the number of senescent cells and extends healthy life. Human trials are ongoing.
Human data
Clinical research on senolytics in humans is at early stages. Known directions:
- Idiopathic pulmonary fibrosis (D+Q).
- Kidney disease and age-related impairments.
- Osteoarthritis and joint aging.
- Assessment of safety and tolerability of fisetin.
How to read this study
What to check so you do not overrate the conclusions.
- Look at design, sample size, control and randomisation
- Check doses, form and duration
- Look for conflicts of interest
- Read limitations, not just the conclusion
Limitations
What limits the applicability of the results.
- Animal models are not humans
- Small samples produce random results
- Different doses and forms complicate comparison
- Publication bias
What this means in practice
How to use the findings safely.
- Do not change treatment based on one study
- Discuss conclusions with a doctor
- Consider your own tests and diseases
- Follow new reviews
What are senolytics?
Agents that selectively destroy senescent ("zombie") cells without harming normal ones.
What is dasatinib?
An approved anticancer drug (tyrosine kinase inhibitor) that shows senolytic activity combined with quercetin.
What is fisetin?
A natural flavonoid from strawberries, apples, persimmons and onions, considered a potent natural senolytic.
Why are senescent cells harmful?
They stopped dividing but release pro-inflammatory signals (SASP), accelerating tissue aging and chronic inflammation.
Do senolytics work in humans?
Clinical trials are at early stages; confirmed efficacy in humans is still limited.
Can dasatinib be taken as a supplement?
No. It is a drug with serious side effects and must not be taken on your own.
Which foods contain fisetin?
Most in strawberries, apples, persimmons and onions.
How do senolytics differ from senostatics?
Senolytics kill senescent cells, while senostatics only suppress their pro-inflammatory activity (SASP).
Who discovered senolytics?
James Kirkland from Mayo Clinic is the pioneer; dasatinib+quercetin were described in 2015.
Should we wait for widespread senolytics?
Promising but still experimental. For now, reducing senescent cell accumulation through lifestyle and diet helps.
What is important to know about Senolytics research?
Senolytics — agents that destroy senescent cells. We review dasatinib+quercetin and fisetin research, early clinical data in humans and prospects.
What should be considered when using Senolytics research?
Consider the form, dose, drug interactions and your health status. With chronic disease, pregnancy or medication — only after consulting a doctor.
Who especially needs to watch Senolytics research?
People with confirmed deficiency, chronic disease, restrictive diets, pregnancy and older adults.
What evidence stands behind Senolytics research?
Look at the study type: cells, animals, observational data or RCTs. For humans, RCTs and meta-analyses matter most.
When should you see a specialist?
See a doctor for worsening symptoms, pain, breathlessness, bleeding, weight loss or neurological problems. Before supplements with chronic disease, book a routine consultation.